Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.